THERAPY OF POST-OPERATIVE EMESIS WITH AMISULPRIDE
Amisulpride is useful in the therapy (particularly the prevention) of postoperative emesis in a patient, particularly wherein the patient is undergoing a surgical procedure where postoperative emesis would be potentially dangerous to the patient.
1 .- 24 . (canceled)
25 . A method for treating or preventing postoperative emesis in a patient, wherein the patient is undergoing a surgical procedure, comprising administering to the patient and effective amount of amisulpride, wherein:
the amisulpride is administered in combination with another anti-emetic, either separately, sequentially or simultaneously,
the dose of amisulpride is 5 mg, and
the patient has at least 3 risk factors for postoperative emesis, wherein the risk factors are selected from a past history of postoperative nausea and vomiting and/or motion sickness; habitual non-smoking status; being a female; and expected use of post-operative opioid analgesia.
26 . The method according to claim 25 , wherein the patient is undergoing a surgical procedure where postoperative emesis would be potentially dangerous to the patient.
27 . The method according to claim 25 , wherein the post-operative emesis would place the patient at risk of aspiration into the lungs, suture dehiscence, oesophageal rupture, subcutaneous emphysema, bilateral pneumothoraxes venous hypertension, increased intracranial pressure, or hematomas.
28 . The method according to claim 27 , wherein the hematomas are those beneath surgical flaps, vascular anastomoses, and aneurysm clips.
29 . The method according to claim 25 , wherein the surgical procedure is selected from surgery of the mouth cavity, surgery of the ear, nose or throat (ENT), surgery of the head or face, surgery of the gastrointestinal (GI) tract, lung surgery, abdominal surgery and bowel surgery.
30 . The method according to claim 29 , wherein the surgery of the mouth cavity is wired jaw surgery or dental surgery.
31 . The method according to claim 29 , wherein the ENT surgery is a tonsillectomy or thyroidectomy.
32 . The method according to claim 29 , wherein the surgery of the head or face is a craniotomy, hemorrhagic stroke surgery, ischemic stroke surgery, rhinoplasty, a cosmetic procedure of the face or eye surgery.
33 . The method according to claim 29 , wherein the GI tract surgery is paraesophageal surgery, anti-reflux surgery, bariatric surgery, gastrectomy, gastric bypass surgery or gastric sleeve surgery.
34 . The method according to claim 29 , wherein the lung surgery is a surgical lung biopsy, lobectomy or wedge resection.
35 . The method according to claim 29 , wherein the abdominal surgery is a surgical hernia repair, a total abdominal hysterectomy, abdominoplasty, laparotomy, any surgery involving a large abdominal incision, or an open abdominal aortic aneurysm repair.
36 . The method according to claim 25 , wherein the other anti-emetic is a 5HT 3 antagonist, an NK 1 antagonist or a steroid.
37 . The method according to claim 25 , wherein the other anti-emetic is dexamethasone, ondansetron, granisetron, palonosetron, aprepitant, netupitant or rolapitant.
38 . The method according to claim 25 , wherein the amisulpride is substantially in the form of a racemate.
39 . The method according to claim 25 , wherein the amisulpride is in the form of (S−)-amisulpride, which is substantially free of the (R+)-enantiomer.
40 . The method according to claim 25 , wherein the amisulpride is administered via the intravenous route.
41 . The method according to claim 40 , wherein the amisulpride is administered by infusion over about 1 to 2 minutes.
42 . The method according to claim 25 , wherein the amisulpride is administered in a single dose.
43 . The method according to claim 25 , wherein the amisulpride is administered at the time of induction of anaesthesia.